MarketCap
Prelude Therapeutics Incorporated PRLD
$ 3.8
0.53%
Facebook
X
Telegram
Prelude Therapeutics Incorporated Long-Term Debt | PRLD
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Prelude Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 M | 15.3 M | 15.4 M | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.4 M | 15 M | 15.3 M |
Quarterly Long-Term Debt Prelude Therapeutics Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 M | 15 M | 15.3 M | 15.1 M | 15.2 M | 15.3 M | 15.4 M | 15.4 M | 15.5 M | 15.5 M | 15.4 M | - | - | - | - | - | - | 390 K | - | 312 K | 543 K | 840 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 M | 312 K | 11.3 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Champions Oncology
CSBR
|
7 K | $ 4.77 | 0.42 % | $ 66 M |  USA |
 |
Fennec Pharmaceuticals
FENC
|
19.3 M | $ 10.7 | 1.13 % | $ 306 M | USA |
|
Forte Biosciences
FBRX
|
26.2 M | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunic
IMUX
|
107 K | $ 8.14 | 1.18 % | $ 1.27 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
4 K | $ 9.67 | 1.06 % | $ 454 M | USA |
 |
Longeveron
LGVN
|
169 K | $ 3.27 | 15.14 % | $ 57.5 B | USA |
 |
Grifols, S.A.
GRFS
|
1.02 B | $ 8.85 | 1.03 % | $ 6.02 B |  Spain |
 |
Incyte Corporation
INCY
|
30.2 M | $ 122.28 | 1.65 % | $ 23.9 B | USA |
 |
AC Immune SA
ACIU
|
3.69 M | $ 2.26 | -1.53 % | $ 228 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
15 M | $ 0.65 | 2.67 % | $ 39 M | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
4.9 M | $ 9.12 | -4.0 % | $ 117 M | USA |
 |
AIM ImmunoTech
AIM
|
927 K | $ 0.15 | 6.3 % | $ 243 K | USA |
 |
MediWound Ltd.
MDWD
|
2.01 M | $ 13.81 | -2.13 % | $ 376 M |  Israel |
 |
Ascendis Pharma A/S
ASND
|
84.6 M | $ 258.99 | 0.94 % | $ 15.7 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
292 M | $ 71.09 | -0.22 % | $ 1.43 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
972 K | $ 1.59 | 1.27 % | $ 49.6 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
66.8 M | $ 1.24 | -6.06 % | $ 330 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
2.01 B | $ 79.53 | 1.09 % | $ 15.2 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
315 M | $ 7.66 | 1.73 % | $ 1.61 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
669 K | $ 3.69 | -0.14 % | $ 256 M | Britain |
 |
Coherus BioSciences
CHRS
|
1.46 M | $ 0.58 | -8.97 % | $ 67.9 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
108 M | $ 28.37 | 3.6 % | $ 3.61 B | USA |
 |
Cellectis S.A.
CLLS
|
27.7 M | $ 1.35 | 21.62 % | $ 135 M |  France |
 |
BeyondSpring
BYSI
|
307 K | $ 0.64 | 10.75 % | $ 26.3 M | USA |
 |
Alkermes plc
ALKS
|
63.3 M | $ 47.94 | 3.16 % | $ 7.9 B |  Irlanda |
 |
Altimmune
ALT
|
34.3 M | $ 1.94 | -0.21 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
102 K | $ 0.76 | -4.57 % | $ 50.8 M | USA |
 |
Novartis AG
NVS
|
1.66 B | $ 160.35 | -1.79 % | $ 311 B | Schweiz |
 |
Citius Pharmaceuticals
CTXR
|
725 K | $ 0.49 | -1.36 % | $ 5.42 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
20.8 M | $ 9.32 | -0.75 % | $ 255 M | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
104 M | $ 49.35 | 0.71 % | $ 6.6 B | USA |
 |
Atara Biotherapeutics
ATRA
|
9.35 M | $ 8.27 | 2.1 % | $ 104 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
52.3 M | $ 16.22 | -0.49 % | $ 2.18 B | Canada |
 |
Cullinan Management
CGEM
|
1.9 M | $ 11.33 | 0.89 % | $ 683 M | USA |
 |
BioNTech SE
BNTX
|
185 M | $ 87.68 | 0.54 % | $ 21.2 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
4.13 M | $ 24.8 | 1.35 % | $ 785 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 3.99 | 1.53 % | $ 53.1 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
383 K | $ 1.24 | 3.33 % | $ 56.7 M | Israel |
 |
AnaptysBio
ANAB
|
10.9 M | $ 48.73 | 0.72 % | $ 1.41 B | USA |
 |
Assembly Biosciences
ASMB
|
2.06 M | $ 22.36 | 4.73 % | $ 251 M | USA |
 |
Adagene
ADAG
|
1.14 M | $ 2.14 | 4.39 % | $ 126 M |  China |
 |
Benitec Biopharma
BNTC
|
266 K | $ 9.47 | 2.05 % | $ 441 M | USA |
 |
Denali Therapeutics
DNLI
|
5.53 M | $ 19.74 | -0.55 % | $ 3.41 B | USA |
 |
Amarin Corporation plc
AMRN
|
6.08 M | $ 11.68 | -0.64 % | $ 4.85 B | Irlanda |
 |
ImmuCell Corporation
ICCC
|
7.49 M | $ 10.19 | -0.7 % | $ 92 M | USA |
 |
Editas Medicine
EDIT
|
53.6 M | $ 2.38 | -4.99 % | $ 211 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
21.8 M | $ 32.84 | 3.38 % | $ 1.9 B | USA |
 |
Cue Biopharma
CUE
|
2.29 M | $ 19.08 | 1.71 % | $ 1.81 B | USA |
 |
Equillium
EQ
|
356 K | $ 1.41 | -3.09 % | $ 80.8 M | USA |